Longitudinal analysis of pupillometry according to type of pharmacotherapy in Parkinson's disease patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10501917" target="_blank" >RIV/00216208:11110/25:10501917 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/25:10501917

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ifr_upcxrJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ifr_upcxrJ</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-025-15306-z" target="_blank" >10.1038/s41598-025-15306-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Longitudinal analysis of pupillometry according to type of pharmacotherapy in Parkinson's disease patients

Popis výsledku v původním jazyce

The aim of this study was to evaluate the effect of different types of pharmacotherapy on pupillometric parameters in PD patients. Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupil diameter may thus serve as an indirect measure of peripheral dopaminergic activity. A total of 63 PD patients were treated with different types of dopaminergic pharmacotherapy. Pupil examination was performed before the first application of dopaminergic pharmacotherapy and then after one year of treatment in the OFF state and in the ON state. There were significant differences in pupillometric parameters obtained at baseline and at year 1 OFF and ON. The pupillometry did not differ among type of used pharmacotherapy in most pupillometric parameters. Two-way ANOVA confirmed the significant effect of visit in the pupillometric parameters MAX and MIN, but did not confirm the significant effect treatment between groups of patients with L-DOPA pharmacotherapy and with dopamine agonist. Linear regression analysis showed significant dose-response relationships between the most pupillometric parameters and L-DOPA equivalent doses in the patients treated with L-DOPA and dopamine agonist. In conclusion, this analysis does not confirm a differential pupillary response according to type of pharmacotherapy in PD patients.

Název v anglickém jazyce

Longitudinal analysis of pupillometry according to type of pharmacotherapy in Parkinson's disease patients

Popis výsledku anglicky

The aim of this study was to evaluate the effect of different types of pharmacotherapy on pupillometric parameters in PD patients. Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupil diameter may thus serve as an indirect measure of peripheral dopaminergic activity. A total of 63 PD patients were treated with different types of dopaminergic pharmacotherapy. Pupil examination was performed before the first application of dopaminergic pharmacotherapy and then after one year of treatment in the OFF state and in the ON state. There were significant differences in pupillometric parameters obtained at baseline and at year 1 OFF and ON. The pupillometry did not differ among type of used pharmacotherapy in most pupillometric parameters. Two-way ANOVA confirmed the significant effect of visit in the pupillometric parameters MAX and MIN, but did not confirm the significant effect treatment between groups of patients with L-DOPA pharmacotherapy and with dopamine agonist. Linear regression analysis showed significant dose-response relationships between the most pupillometric parameters and L-DOPA equivalent doses in the patients treated with L-DOPA and dopamine agonist. In conclusion, this analysis does not confirm a differential pupillary response according to type of pharmacotherapy in PD patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scientific Reports

ISSN

2045-2322

e-ISSN

2045-2322

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

30525

Kód UT WoS článku

001577164900036

EID výsledku v databázi Scopus

2-s2.0-105013870594